12 November 2024
AstraZeneca invests $3.5
billion
in R&D and manufacturing
in the United States
AstraZeneca today announces $3.5 billion of capital investment
in the United States focused on expanding the Company's research
and manufacturing footprint by the end of 2026. This includes $2
billion of new investment creating more than a thousand new,
high-skilled jobs contributing to the growth of the US
economy.
AstraZeneca's expanding footprint
in the US includes, among others:
·
A state-of-the-art R&D centre in Kendall
Square, Cambridge, Massachusetts
·
A next generation manufacturing facility for
biologics in Maryland
·
Cell therapy manufacturing capacity on the West
and East Coasts
·
Specialty manufacturing in Texas
Pascal Soriot, Chief Executive
Officer, AstraZeneca said: "Our
multibillion dollar investment reflects the attractiveness of the
business environment together with the quality of talent and
innovation capabilities here in the United States. By expanding our
R&D and manufacturing footprint, we aim to enhance the
development of cutting-edge therapies and support the United States
leadership in healthcare innovation."
Delivering growth: Ambition
2030
These US investments are the first
of a series of important steps to help deliver AstraZeneca's
ambition to achieve $80 billion in Total Revenue by 2030 as set out
in
May this year.
A key element of our strategy is accelerating the
Company's development in the United States. The US is AstraZeneca's
largest market, generating 44% of its Total
Revenue.1
AstraZeneca in the US
AstraZeneca has approximately 17,800
employees working across 17 R&D, manufacturing and commercial
sites spanning 12 states.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and follow
the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. As at Q3
2024 noted in AstraZeneca Q3 Financial Results. Available
at:
https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html.
Accessed November 2024.
Adrian Kemp
Company Secretary
AstraZeneca PLC